Theravance Biopharma Inc
(STU:0TB)
€
8.85
-0.1 (-1.11%)
Market Cap: 430.25 Mil
Enterprise Value: 393.40 Mil
PE Ratio: 0
PB Ratio: 2.45
GF Score: 69/100 Theravance Biopharma Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019 / 03:05PM GMT
Release Date Price:
€19.3
(-0.87%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
Welcome to the healthcare conference. I'm Jeff Hung one of the biotech analysts. Before we start, please note that all important disclosures including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at www.morganstanley.com/research disclosures, or at the registration desk. For this session, we have from Theravance Biopharma, Rick Winningham, CEO; Andrew Hindman, CFO; and Brett Haumann, CMO. Welcome.
Rick E. Winningham
Theravance Biopharma, Inc. - Chairman & CEO
Thank you. Thank you. Glad to be here.
Questions & Answers
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
So as of this morning -- as this morning showed, the 12 to 16 months are going to be data-rich free-er companies, so we have a lot of ground to cover. But maybe first, for those who are in the room who are not as familiar with
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot